Daniel OConnor - Eagle Pharmaceuticals Chief VP
Insider
Daniel OConnor is Chief VP of Eagle Pharmaceuticals
| Age | 44 |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Eagle Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eagle Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eagle Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eagle to invest in growth at high rates of return. When we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Wai Chung | Regencell Bioscience Holdings | 48 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Jean Filippi | Phibro Animal Health | N/A | |
| Yongfeng Zhang | Amphastar P | 78 | |
| Thomas Harvey | Alkermes Plc | N/A | |
| David Erickson | Evolus Inc | N/A | |
| Christopher Coughlin | Prestige Brand Holdings | 67 | |
| Damian Finio | Phibro Animal Health | 54 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Adel Mekhail | Prestige Brand Holdings | 64 | |
| Jacob MBA | Amphastar P | 50 | |
| Philip Terpolilli | Prestige Brand Holdings | N/A | |
| Dean Siegal | Prestige Brand Holdings | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Jeffrey Zerillo | Prestige Brand Holdings | 63 | |
| Peter Langosh | Amphastar P | 71 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| YatGai Au | Regencell Bioscience Holdings | 52 | |
| Sandra Beaver | Evolus Inc | 47 | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Gaozhong Zhu, Senior Development | ||
| Reiner Nowak, Exec | ||
| Ryan Debski, General VP | ||
| John Kimmet, Ex Care | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| Valentin MD, Senior Development | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |